JPWO2022025264A1 - - Google Patents
Info
- Publication number
- JPWO2022025264A1 JPWO2022025264A1 JP2022539616A JP2022539616A JPWO2022025264A1 JP WO2022025264 A1 JPWO2022025264 A1 JP WO2022025264A1 JP 2022539616 A JP2022539616 A JP 2022539616A JP 2022539616 A JP2022539616 A JP 2022539616A JP WO2022025264 A1 JPWO2022025264 A1 JP WO2022025264A1
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/102—Coronaviridae (F)
- C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020131022 | 2020-07-31 | ||
| JP2020131022 | 2020-07-31 | ||
| PCT/JP2021/028366 WO2022025264A1 (ja) | 2020-07-31 | 2021-07-30 | ＳＡＲＳ－ＣｏＶ－２由来のアミノ酸配列およびその利用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2022025264A1 true JPWO2022025264A1 (https=) | 2022-02-03 |
| JP7747273B2 JP7747273B2 (ja) | 2025-10-01 |
Family
ID=80035853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022539616A Active JP7747273B2 (ja) | 2020-07-31 | 2021-07-30 | ＳＡＲＳ－ＣｏＶ－２由来のアミノ酸配列およびその利用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230272005A1 (https=) |
| EP (1) | EP4190799A4 (https=) |
| JP (1) | JP7747273B2 (https=) |
| CN (1) | CN116157411A (https=) |
| WO (1) | WO2022025264A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022308712A1 (en) * | 2021-07-09 | 2023-12-21 | Atossa Therapeutics, Inc. | Compositions and methods to increase coronavirus immune response |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020028219A (ja) * | 2016-11-11 | 2020-02-27 | 大日本住友製薬株式会社 | マラリアワクチン |
| WO2021188969A2 (en) * | 2020-03-20 | 2021-09-23 | Biontech Us Inc. | Coronavirus vaccines and methods of use |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1609119A (zh) * | 2003-10-23 | 2005-04-27 | 中国医学科学院药物研究所 | 一种肽文库、其合成方法及从该文库中筛选的活性片段 |
| JP7297697B2 (ja) | 2019-02-19 | 2023-06-26 | キヤノンメディカルシステムズ株式会社 | 神経活動の領域を推定する推定方法、推定装置及び磁気共鳴イメージング装置 |
| BR102019017792A2 (pt) * | 2019-08-27 | 2021-11-16 | Fundação Oswaldo Cruz | Receptáculo proteico, método para produção do receptáculo, método de identificação de patógenos ou de diagnóstico de doenças, e, uso do receptáculo |
| JP2023512519A (ja) * | 2020-01-31 | 2023-03-27 | ベス イスラエル ディーコネス メディカル センター インコーポレイテッド | コロナウイルス感染症を予防および処置するための組成物および方法－ｓａｒｓ－ｃｏｖ－２ワクチン |
| WO2021181390A1 (en) * | 2020-03-09 | 2021-09-16 | Vaxil Biotherapeutics Ltd. | Antigen specific epitope–based anti-infective vaccines |
-
2021
- 2021-07-30 WO PCT/JP2021/028366 patent/WO2022025264A1/ja not_active Ceased
- 2021-07-30 US US18/007,092 patent/US20230272005A1/en active Pending
- 2021-07-30 JP JP2022539616A patent/JP7747273B2/ja active Active
- 2021-07-30 EP EP21851571.6A patent/EP4190799A4/en active Pending
- 2021-07-30 CN CN202180058673.0A patent/CN116157411A/zh active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020028219A (ja) * | 2016-11-11 | 2020-02-27 | 大日本住友製薬株式会社 | マラリアワクチン |
| WO2021188969A2 (en) * | 2020-03-20 | 2021-09-23 | Biontech Us Inc. | Coronavirus vaccines and methods of use |
Non-Patent Citations (5)
| Title |
|---|
| KHAN, M. IMRAN ET AL.: "Reports of Coding-Complete Genome Sequences of Five 2019 Novel Coronavirus (SARS-CoV-2) Strains Isol", MICROBIOLOGY RESOURCE ANNOUNCEMENTS, vol. Vol.9, Issue 31, JPN7021003948, 30 July 2020 (2020-07-30), pages 00692 - 20, ISSN: 0005599981 * |
| MISHRA, SEEMA: "T cell epitope-based vaccine design for pandemic novel coronavirus 2019-nCoV across structural and n", CHEMRXIV, BIOLOGICAL AND MEDICINAL CHEMISTRY [ONLINE], JPN7021003944, 3 April 2020 (2020-04-03), ISSN: 0005599977 * |
| SINGH, ABHISHEK ET AL.: "Designing a multi-epitope peptide-based vaccine against SARS-CoV-2", BIORXIV [ONLINE], JPN7021003945, 16 April 2020 (2020-04-16), ISSN: 0005599978 * |
| UL QAMAR, MUHAMMAD TAHIR ET AL.: "Designing of a next generation multiepitope based vaccine (MEV) against SARS-COV-2: Immunoinformati", BIORXIV [ONLINE], JPN7021003947, 22 March 2020 (2020-03-22), ISSN: 0005599980 * |
| YOSHIDA, SHOTA ET AL.: "SARS-CoV-2-induced humoral immunity through B cell epitope analysis and neutralizing activity in COV", BIORXIV [ONLINE], JPN7021003946, 23 July 2020 (2020-07-23), ISSN: 0005599979 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP7747273B2 (ja) | 2025-10-01 |
| WO2022025264A1 (ja) | 2022-02-03 |
| EP4190799A1 (en) | 2023-06-07 |
| US20230272005A1 (en) | 2023-08-31 |
| CN116157411A (zh) | 2023-05-23 |
| EP4190799A4 (en) | 2024-08-21 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AA64 | Notification of invalidation of claim of internal priority (with term) |
Free format text: JAPANESE INTERMEDIATE CODE: A241764 Effective date: 20230406 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230421 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240605 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250522 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250718 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20250814 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20250909 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7747273 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |